MedTrace Logo

Influences of Angiotensin-neprilysin Inhibition on Sympathetic Activity in Heart Failure

NCT03415906 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-10-09

No results posted yet for this study

Summary

The autonomic nervous system plays an important role in controlling the circulation. Increased sympathetic activity has detrimental effects in patients with heart failure.

The purpose of this study is to test the hypothesis that combined angiotensin receptor + neprilysin inhibition results in lower sympathetic activity than angiotensin receptor inhibition alone.

Conditions

Interventions

COMBINATION_PRODUCT

sacubitril+valsartan

Combined angiotensin receptor + neprilysin inhibition

DRUG

valsartan

Angiotensin receptor inhibition alone

Sponsors & Collaborators

  • DLR German Aerospace Center

    collaborator OTHER

  • Hannover Medical School

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-14
Primary Completion
2018-09-06
Completion
2018-09-06

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03415906 on ClinicalTrials.gov